A detailed history of Oppenheimer Asset Management Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 39,263 shares of LLY stock, worth $30 Million. This represents 0.43% of its overall portfolio holdings.

Number of Shares
39,263
Previous 39,390 0.32%
Holding current value
$30 Million
Previous $35.7 Million 2.46%
% of portfolio
0.43%
Previous 0.47%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$772.14 - $960.02 $98,061 - $121,922
-127 Reduced 0.32%
39,263 $34.8 Million
Q2 2024

Aug 08, 2024

BUY
$724.87 - $909.04 $2.28 Million - $2.86 Million
3,151 Added 8.7%
39,390 $35.7 Million
Q1 2024

May 06, 2024

SELL
$592.2 - $792.28 $2.36 Million - $3.16 Million
-3,993 Reduced 9.92%
36,239 $28.2 Million
Q4 2023

Feb 13, 2024

SELL
$525.19 - $619.13 $88,231 - $104,013
-168 Reduced 0.42%
40,232 $23.5 Million
Q3 2023

Nov 07, 2023

SELL
$434.7 - $599.3 $918,955 - $1.27 Million
-2,114 Reduced 4.97%
40,400 $21.7 Million
Q2 2023

Aug 02, 2023

SELL
$350.74 - $468.98 $288,308 - $385,501
-822 Reduced 1.9%
42,514 $19.9 Million
Q1 2023

May 10, 2023

BUY
$310.63 - $364.82 $440,162 - $516,949
1,417 Added 3.38%
43,336 $14.9 Million
Q4 2022

Feb 06, 2023

SELL
$321.55 - $374.67 $321,871 - $375,044
-1,001 Reduced 2.33%
41,919 $15.3 Million
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $6.66 Million - $7.59 Million
-22,455 Reduced 34.35%
42,920 $13.9 Million
Q2 2022

Aug 08, 2022

SELL
$278.73 - $327.27 $6.17 Million - $7.24 Million
-22,129 Reduced 25.29%
65,375 $21.2 Million
Q1 2022

May 12, 2022

BUY
$234.69 - $291.66 $3.77 Million - $4.68 Million
16,051 Added 22.46%
87,504 $25.1 Million
Q4 2021

Feb 02, 2022

SELL
$224.85 - $279.04 $174,483 - $216,535
-776 Reduced 1.07%
71,453 $19.7 Million
Q3 2021

Nov 12, 2021

SELL
$221.6 - $272.71 $3.67 Million - $4.52 Million
-16,561 Reduced 18.65%
72,229 $16.7 Million
Q2 2021

Aug 03, 2021

BUY
$180.55 - $233.54 $900,583 - $1.16 Million
4,988 Added 5.95%
88,790 $20.4 Million
Q1 2021

May 17, 2021

SELL
$164.32 - $212.72 $2.92 Million - $3.78 Million
-17,791 Reduced 17.51%
83,802 $15.7 Million
Q4 2020

Feb 11, 2021

SELL
$130.46 - $172.63 $651,778 - $862,459
-4,996 Reduced 4.69%
101,593 $17.2 Million
Q3 2020

Nov 13, 2020

SELL
$146.22 - $169.13 $3.67 Million - $4.25 Million
-25,121 Reduced 19.07%
106,589 $15.8 Million
Q2 2020

Aug 11, 2020

SELL
$136.42 - $164.18 $7.5 Million - $9.03 Million
-55,009 Reduced 29.46%
131,710 $21.6 Million
Q1 2020

May 08, 2020

SELL
$119.05 - $147.35 $925,494 - $1.15 Million
-7,774 Reduced 4.0%
186,719 $25.9 Million
Q4 2019

Feb 07, 2020

SELL
$106.92 - $132.43 $3.81 Million - $4.72 Million
-35,624 Reduced 15.48%
194,493 $25.6 Million
Q3 2019

Oct 31, 2019

SELL
$106.79 - $116.16 $790,032 - $859,351
-7,398 Reduced 3.11%
230,117 $25.7 Million
Q2 2019

Aug 09, 2019

SELL
$110.79 - $129.32 $976,946 - $1.14 Million
-8,818 Reduced 3.58%
237,515 $26.3 Million
Q1 2019

Apr 24, 2019

SELL
$111.31 - $131.02 $6.63 Million - $7.81 Million
-59,605 Reduced 19.48%
246,333 $32 Million
Q4 2018

Jan 30, 2019

SELL
$105.9 - $118.64 $213,494 - $239,178
-2,016 Reduced 0.65%
305,938 $35.4 Million
Q3 2018

Oct 26, 2018

BUY
$85.86 - $107.31 $571,398 - $714,148
6,655 Added 2.21%
307,954 $33 Million
Q2 2018

Aug 10, 2018

SELL
$75.7 - $86.88 $1.35 Million - $1.55 Million
-17,897 Reduced 5.61%
301,299 $25.7 Million
Q1 2018

May 09, 2018

BUY
$74.21 - $87.6 $341,514 - $403,135
4,602 Added 1.46%
319,196 $24.7 Million
Q3 2017

Nov 14, 2017

BUY
$77.07 - $85.54 $24.2 Million - $26.9 Million
314,594
314,594 $26.9 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $727B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.